Synergistic Enhancement of Antitumor Effects by Combining Abemaciclib with Desipramine
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25137407 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Yan Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Technology Convergence, National Cancer Center, 323 Ilsan-ro, Goyang 10408, Gyeonggi-Do, Republic of Korea. Hauptthemen laut MEDLINE: Benzimidazoles, Aminopyridines, Drug Synergism, Xenograft Model Antitumor Assays. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Cancer Center.
Abstract (Originalsprache)
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, including abemaciclib, have been approved for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced, and metastatic breast cancer. Despite the high therapeutic efficacy of CDK4/6 inhibitors, they are associated with various adverse effects, including potentially fatal interstitial lung disease. Therefore, a combination of CDK4/6 inhibitors with letrozole or fulvestrant has been attempted but has demonstrated limitations in reducing adverse effects, highlighting the need to develop new combination therapies. This study proposes a combination strategy using CDK4/6 inhibitors and tricyclic antidepressants to enhance the therapeutic outcomes of these inhibitors while reducing their side effects. The therapeutic efficacies of abemaciclib and desipramine were tested in different cancer cell lines (H460, MCF7, and HCT-116). The antitumor effects of the combined abemaciclib and desipramine treatment were evaluated in a xenograft colon tumor model. In vitro cell studies have shown the synergistic anticancer effects of combination therapy in the HCT-116 cell line. The combination treatment significantly reduced tumor size compared with control or single treatment without causing apparent toxicity to normal tissues. Although additional in vivo studies are necessary, this study suggests that the combination therapy of abemaciclib and desipramine may represent a novel therapeutic approach for treating solid tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Technology Convergence, National Cancer Center, 323 Ilsan-ro, Goyang 10408, Gyeonggi-Do, Republic of Korea.
- Division of Cancer Biology, National Cancer Center, 323 Ilsan-ro, Goyang 10408, Gyeonggi-Do, Republic of Korea.
ORCID-Profile: Young Eun Choi, Sung-Ho Goh
Förderung
- National Cancer Center
Zitieren
APA
Li, Y., Sung, Y., Choi, Y. E., Choi, Y., & Goh, S. H. (2024). Synergistic Enhancement of Antitumor Effects by Combining Abemaciclib with Desipramine. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25137407
Vancouver
Li Y, Sung Y, Choi YE, Choi Y, Goh SH. Synergistic Enhancement of Antitumor Effects by Combining Abemaciclib with Desipramine. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25137407
BibTeX
@article{Li2024,
author = {Li, Yan and Sung, Yeojin and Choi, Young Eun and Choi, Yongdoo and Goh, Sung-Ho},
title = {Synergistic Enhancement of Antitumor Effects by Combining Abemaciclib with Desipramine},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25137407}
}
EUVIMED